Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.

Key Concepts

• Medicare and Medicaid coverage for weight loss drugs
• Cost reduction for Zepbound and Wegovy
• Most Favored Nations (MFN) rates
• GLP-1 weight loss drugs (oral)
• Price disparities between US and Europe

Medicare and Medicaid Coverage for Weight Loss Drugs

Medicare and Medicaid will now cover the cost of certain weight loss drugs, a significant development that will impact millions of patients. Previously, these medications often incurred out-of-pocket costs exceeding $1,000 per month for consumers. This new coverage aims to make these treatments more accessible and affordable.

Cost Reduction for Zepbound and Wegovy

Eli Lilly and Novo Nordisk, the manufacturers of Zepbound and Wegovy respectively, have committed to offering these drugs at "most favored nations" (MFN) rates. This agreement is expected to drastically reduce the cost of these medications for American consumers.

• Wegovy: The monthly cost will be reduced from $1,350 to an ultimate price of $250.
• Zepbound: The monthly cost will be reduced from $1,080 to $346.

These reductions represent significant savings, with Wegovy potentially seeing a decrease of over 80% and Zepbound a decrease of over 65%. The transcript notes that Americans have been spending as much as 520% more for Zepbound and 1,400% more for Wegovy than patients in Europe, highlighting the substantial price disparity that this new policy aims to address.

Future GLP-1 Weight Loss Drugs

In addition to the current medications, both Eli Lilly and Novo Nordisk have committed to offering future GLP-1 weight loss drugs that are taken orally. These oral formulations, currently under development, will be sold at a maximum price of $149 per month. This commitment suggests a continued effort to make weight loss therapies more affordable and accessible as new options become available.

Synthesis/Conclusion

The announcement of Medicare and Medicaid coverage for weight loss drugs, coupled with significant price reductions for Zepbound and Wegovy through the implementation of Most Favored Nations rates, marks a pivotal moment in the accessibility of these treatments. The commitment to cap the price of future oral GLP-1 weight loss drugs at $149 per month further underscores a strategic shift towards affordability. These changes are expected to alleviate the substantial financial burden previously faced by many patients and address the considerable price differences observed between the US and European markets.